Navigation Links
Enigma Diagnostics and GSK Announce Collaboration on Assay Development and Commercialization of Enigma's ML Platform
Date:8/10/2011

LONDON and OXFORD, England, Aug. 10, 2011 /PRNewswire/ -- Enigma Diagnostics Limited (Enigma) and GlaxoSmithKline (GSK) today announced that they have signed agreements for the supply and commercialization on an exclusive basis of the Enigma® ML system in Europe and other designated key countries, including India, Brazil and Russia. The agreements include development by Enigma of an initial range of respiratory tests for use on its real-time Polymerase Chain Reaction (PCR) technology platform, and provide GSK the opportunity to generate revenues from further test developments in infectious diseases and in other therapeutic areas relevant to its healthcare business.  

The Enigma® ML system has the potential to deliver a result from a raw sample in under 60 minutes in a point of need setting. The new collaboration significantly extends the scope of the Influenza partnership announced in July 2009 for the Enigma® ML system and builds on GSK's extensive expertise and heritage within the respiratory therapeutic area and the extended capabilities offered by the Enigma® ML system.  

Under the terms of this agreement, GSK will make an additional equity investment and upfront payment, R&D-related payments, and royalties on net sales of resulting products. Additional payments will be subject to agreed commercialization milestones.

John McKinley, Chairman and CEO of Enigma, said: "This is a major collaboration and represents a significant milestone for Enigma. These agreements for assay development, commercialization and supply will leverage GSK's extensive sales and marketing force with Enigma's unique Point of Care system which has potential uses across a number of human diseases. This is a partnership which will deliver much needed "test and treat" capability to infectious disease management."

Eddie Gray, President, Pharmaceuticals Europe of GSK said: "GSK is committed to improving the lives of patients suffering from respiratory and other diseases by providing truly innovative healthcare solutions to improve the care of these vulnerable patient populations.  The collaboration with Enigma provides GSK the opportunity to offer a more complete solution to the healthcare community and improve patient care through the provision of rapid, state of the art diagnostic tests."

Notes to Editors

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com    

Enigma Diagnostics Limited & The Enigma® ML system

Enigma specializes in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Enigma's first IVD instrument is the Enigma® ML system which will deliver raw sample to result diagnostic testing in less than 60 minutes and provide accuracy standards comparable with reference laboratories.  Operators of the Enigma ML system will not require specialist training allowing the system to be used in a broad range of settings in both developed and emerging healthcare countries.  The Company is developing leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies that are underpinned by its broad Intellectual Property portfolio.  For more information visit www.enigmadiagnostics.com    

Polymerase Chain Reaction technology (PCR) is a widely used & highly specific diagnostic technique in which a few copies of target DNA are amplified to generate millions of copies of the specific DNA sequence making it easier to identify the sample.

Enigma Press Contact:
Tatjana Quinn
Telephone: + 44 (0)1235 854076
tatjana.quinn@enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Enigma Diagnostics Showcases Its Unique Fully Automated rtPCR Based ML (Mini-Laboratory) Instrument For Point-of-Care Testing at MEDICA 2009 In Dusseldorf, Germany
2. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
3. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
6. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
7. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
10. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
11. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... Pipeline Review, H1 2016" is a report that ... and helps strengthen R&D pipelines by identifying new ... products. Company Profiles discussed in this ... Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... ... 29, 2016 , ... World Patent Marketing , a ... invention which aids in proper muscle development. , "The Gym & Exercise Equipment ... of World Patent Marketing. "Globalization has threatened the future growth of the industry ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although ... the majority of skin cancer deaths. More than 10,000 people are expected to die of ... is 62, it is the one of the most commonly diagnosed cancers in young women. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... is a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to ... is a procedure that involves one or both jaw bones. This surgery is performed to ...
Breaking Medicine News(10 mins):